Literature DB >> 17188779

Toxicological overview of impurities in pharmaceutical products.

David Jacobson-Kram1, Timothy McGovern.   

Abstract

While the use of pharmaceuticals is always a balance of risks and benefits, the same is not true for impurities in pharmaceuticals; impurities convey only risk. A number of international guidelines and regional guidances instruct drug developers and regulatory agencies on how to evaluate and control impurities in drug substances and drug products. While impurities should always be reduced to the lowest levels that are reasonably practical, it is acknowledged that impurities cannot be reduced to zero and specifications for impurities need to be established. This chapter discusses practical and theoretical methods for qualification of different classes of impurities.

Mesh:

Substances:

Year:  2006        PMID: 17188779     DOI: 10.1016/j.addr.2006.10.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  3 in total

1.  Characterization of forced degradation products of toloxatone by LC-ESI-MS/MS.

Authors:  Robert Skibiński; Jakub Trawiński; Łukasz Komsta; Diana Murzec
Journal:  Saudi Pharm J       Date:  2018-02-06       Impact factor: 4.330

2.  Organic Salts of Pharmaceutical Impurity p-Aminophenol.

Authors:  U B Rao Khandavilli; Leila Keshavarz; Eliška Skořepová; René R E Steendam; Patrick J Frawley
Journal:  Molecules       Date:  2020-04-21       Impact factor: 4.411

3.  Identification of unknown impurity of azelaic acid in liposomal formulation assessed by HPLC-ELSD, GC-FID, and GC-MS.

Authors:  Stanisław Han; Katarzyna Karłowicz-Bodalska; Piotr Potaczek; Adam Wójcik; Lukasz Ozimek; Dorota Szura; Witold Musiał
Journal:  AAPS PharmSciTech       Date:  2013-10-29       Impact factor: 3.246

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.